A Dose-Escalation Study to Assess the Safety and Tolerability of LX214 Ophthalmic Solution in Healthy Volunteers, Followed by an Open-Label Evaluation of LX214 in Patients With Keratoconjunctivitis Sicca (KCS)

Inclusion Criteria: * No systemic disease as determined by a physical examination, clinical laboratory evaluation, and an ECG * Schirmer's I Test ≥ 10mm/5 minutes with anesthesia * Corrected Snellen acuity of 20/40 or better in both eyes Exclusion Criteria: * Subjects diagnosed with any ocular disease other than refraction error * Subjects with intraocular pressure \>21 mmHg * Use of a contact lens within 7 days prior to administration of the first dose * Subjects with history of ocular surgery * Subjects with a history of laser refractive surgery